According to filings with the U.S. Securities and Exchange Commission, Orgenesis is raising $1,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Vered Caplan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Orgenesis
Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships its CGTs to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.

To learn more about Orgenesis, visit http://www.orgenesis.com/

Contact:
Vered Caplan, President and Chief Executive Officer
480-659-6404
https://www.linkedin.com/in/vered-caplan-4366928/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.